This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Echo Therapeutics Hires Marketing Executive

PHILADELPHIA, May 30, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced that David Walton, who has nearly two decades of strategic healthcare marketing experience, has joined Echo Therapeutics' management team at a critical stage in company growth.  Mr. Walton will report to CEO Patrick Mooney, M.D.

David Walton joins as Vice President of Marketing and Commercial Development, leading global strategic marketing planning for Echo's Symphony tCGM System and other new products in the Company's growth strategy.

"We are extremely pleased to welcome David to Echo's management team.  Dave brings an extensive track record of business strategy, healthcare marketing, and product development expertise to Echo," said Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. "We look forward to benefiting from Dave's substantial knowledge to lead Symphony from product development to global commercialization."

Mr. Walton brings 17 years of healthcare marketing and strategic planning experience to Echo. He joins Echo from Johnson & Johnson's Diabetes Care Franchise, where he most recently served as Worldwide Director, Global Strategic Marketing for Insulin Delivery and Continuous Glucose Monitoring products at LifeScan. During his 11 years at J&J, he worked in a number of therapeutic areas, including Diabetes, ADHD, Parkinson's Disease and Oncology and has received several J&J Standards of Leadership Awards.  Prior to J&J, Mr. Walton spent 6 years in healthcare consulting at Deloitte Consulting and Bogart Delafield Ferrier working on various strategy and marketing engagements for health plans, hospital systems and pharmaceutical, biotech and medical device clients.  He earned his BA degree in Psychology from Princeton University and an MBA in Healthcare Management from the Wharton School at the University of Pennsylvania. 

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.30 -0.92%
FB $118.08 0.55%
GOOG $695.81 0.50%
TSLA $234.18 0.80%
YHOO $35.97 -0.11%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs